Clinical Outcome of Targeted Therapy with Gefitinib in Metastatic NSCLC Depending on the Type of EGFR Mutation: A REASON Subgroup Analysis by Exon.

7. Juni 2016

Schuette, W., Dietel, M., Thomas, M., Eberhardt, W., Zirrgiebel, U., Radke, S., Schirmacher, P., 2016.

Oncol Res Treat, 39 (suppl 1), (ID 0341) 120. doi:10.1159/000444354